Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.
Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.
Kura Oncology (Nasdaq: KURA) reported Q2 2024 financial results and provided a corporate update. Key highlights:
- Completed enrollment in KOMET-001 trial of ziftomenib in R/R NPM1-mutant AML; topline data expected in early 2025
- Received Breakthrough Therapy Designation for ziftomenib in R/R NPM1-mutant AML
- Phase 1b expansion study of ziftomenib combinations now enrolling
- IND cleared for ziftomenib in GIST; proof-of-concept study to begin in early 2025
- First patient dosed in KO-2806 and adagrasib combination study in NSCLC
- $491.5 million cash runway into 2027
Q2 2024 financials: R&D expenses $39.7M, G&A expenses $16.7M, net loss $50.8M
Kura Oncology (Nasdaq: KURA) announced FDA clearance of an IND application for ziftomenib, their menin inhibitor, to treat advanced gastrointestinal stromal tumors (GIST). A Phase 1 study combining ziftomenib with imatinib is planned for early 2025. Preclinical data suggest this combination could resensitize patients to imatinib and induce durable responses in imatinib-resistant cases. GIST, the most common sarcoma, is typically treated with KIT inhibitors like imatinib. However, many patients develop resistance, limiting treatment options. Ziftomenib targets the menin-MLL complex, which regulates KIT expression in GIST cells. This marks the first IND clearance for a menin inhibitor in GIST treatment, potentially offering a new approach for patients with options.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. financial markets close. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and provide a corporate update.
Interested parties can access the live call by dialing (877) 300-8521 (domestic) or (412) 317-6026 (international). A live webcast and archived replay of the event will be available on the company's website at www.kuraoncology.com in the investor relations section.
Kura Oncology, a clinical-stage biopharmaceutical company, announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4) on July 1, 2024. The Compensation Committee granted nonstatutory stock options to purchase 128,700 shares of common stock to eight new employees under the 2023 Inducement Option Plan. These options have an exercise price of $21.20 per share, matching the closing sales price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder monthly over the following 36 months, subject to continuous service.
Kura Oncology has presented preclinical data showing the potential of menin inhibitors, specifically ziftomenib, in treating type 2 diabetes. The findings, shared at the American Diabetes Association’s 84th Scientific Sessions, highlight ziftomenib's ability to enhance pancreatic function, boost insulin production, and improve insulin sensitivity in preclinical models. Notably, the therapeutic effects persisted even after stopping the dose, indicating a possible restoration of beta-cell mass. Kura is also developing next-generation menin inhibitors targeting diabetes and other metabolic diseases, in addition to its ongoing clinical trials in acute leukemias.
Kura Oncology announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 3, 2024, the Compensation Committee awarded nonstatutory stock options to purchase 152,500 shares of common stock to eight new employees under the 2023 Inducement Option Plan. The exercise price for each option is $21.19 per share, matching the closing sales price on the grant date. The options vest over four years—25% after one year and the remainder monthly over the next 36 months, contingent on continued employment. These inducement awards aim to attract and retain talent effectively.
Kura Oncology, a clinical-stage biopharmaceutical company, has announced its participation in the Jefferies Global Healthcare Conference.
Troy Wilson, President and CEO, will engage in a virtual fireside chat on June 5, 2024, at 3:00 p.m. ET / 12:00 p.m. PT.
A live audio webcast and an archived replay will be accessible in the Investors section of Kura's website.
Kura Oncology has completed enrollment of 85 patients in its Phase 2 KOMET-001 clinical trial, targeting relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML), within 16 months.
The trial focuses on assessing the clinical activity, safety, and tolerability of their menin inhibitor, ziftomenib (KO-539). Topline data is expected in early 2025.
Notably, ziftomenib has received Breakthrough Therapy Designation from the FDA, which aims to expedite the review process for new drug applications due to its potential efficacy in treating R/R NPM1-mutant AML.
This milestone underscores the urgent need for effective treatment options in AML and highlights ziftomenib's potential to become a best-in-class treatment.
Kura Oncology, Inc. (Nasdaq: KURA) will participate in Bank of America Securities 2024 Healthcare Conference, with the company's President and CEO scheduled for a virtual fireside chat. The event will take place on May 15, 2024, providing investors with insights into the company's progress and future prospects.